Navigation Links
Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
Date:8/22/2013

development-and-worldwide-license-agreement-for-investigational-anti-cancer-drug-pci-32765">December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our futu
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
4. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
5. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
6. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
7. Physicians Expect More Out of Tablet-Toting Pharmaceutical Sales Reps, Study Finds
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
10. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
11. Recent Study Reveals Physicians Prefer Topical Delivery for Drug Delivery Technology, Such as a Transdermal Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ... EU Pharmacovigilance Legislation (London, UK - November 16-17, 2015)" ... 15 new EU modules concerning Pharmacovigilance are a major ... in Europe . The intention of ... their requirements, examine how they overlap and fit together ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of noninvasive medical ... neurological conditions, said today that it has received a ... Affordable Care Act to further the company,s ongoing clinical ... sports concussions. The Therapeutic Discovery grant was ...
... ATLANTA, Nov. 18, 2010 UCB, Inc., ... medications to treat immunology disorders, today announced the winners ... for outstanding individuals affected by this condition. UCB is ... deserving students seek personal growth through higher education. ...
Cached Medicine Technology:Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions 2Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions 32010 UCB Rheumatoid Arthritis Family Scholarship Winners Announced 22010 UCB Rheumatoid Arthritis Family Scholarship Winners Announced 32010 UCB Rheumatoid Arthritis Family Scholarship Winners Announced 4
(Date:9/3/2015)... ... 2015 , ... Global Vision , the world leader in the development ... print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. ... London, booth #F33 , Be the first to get a sneak peek of Intelligent ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers ... Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free ... friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... A scar is an unavoidable result of ... near-miraculous example of the body's ability to heal itself. The appearance of a scar is ... the individual's age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their ...
(Date:9/3/2015)... ... 03, 2015 , ... Representatives with State Farm Agent EJ ... Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing information ... beyond. We will be discussing setting up college funds, offering information specific to ...
(Date:9/3/2015)... Santa Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases ... annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While ... increases to six of every 10 men by age 65, according to the American ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... YORK The Max Cure Foundation and the Samuel Waxman Cancer ... cancer research. With that goal in mind, the two Foundations ... G. Van Meir, Ph.D., of Emory University School of Medicine ... using a small molecule that will target the Ewing sarcoma ...
... July 1 issue of the journal SLEEP shows that ... vigor, fatigue and mood in collegiate basketball players. The ... the athletic performance of actively competing athletes. Results ... time per night during sleep extension was 110.9 minutes ...
... awarded $2.4 million to Allina Hospitals & Clinics to ... pain management for patients at Abbott Northwestern Hospital in ... Health and Healing and the Center for Healthcare Innovation ... study. "Integrative medicine emphasizes a full range of ...
... the Salk Institute for Biological Studies have found clues to ... The protein, p53, can cause cells to stop dividing or ... damage, and it is responsible for much of the tissue ... such as the ones commonly used for cancer therapy. The ...
... the foot just before ground contact during running and walking ... a new study published by a University of Georgia kinesiology ... the June online edition of the American Journal of ... of repetitive ankle sprains demonstrated lower clearance heights between their ...
... June 30 (HealthDay News) -- Women diagnosed with breast cancer ... rates than women who just have breast cancer, according to ... cancer but no chronic illness, those who had conditions such ... or lower survival rate, the study authors reported in the ...
Cached Medicine News:Health News:Targeting the Ewing sarcoma family of tumors 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 3Health News:Allina receives NIH grant to study real world usage of integrative therapies 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:Foot positioning during walking and running may influence ankle sprains 2Health News:Breast Cancer Plus Other Health Issues Linked to Worse Outcomes 2
Transcranial vascular DWL doppler....
... 9100HS is a powerful automated system capable ... Choose from 6 user-programmable test protocols to ... exam. Any tests not included in the ... be handled using the Doppler, PVR and ...
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... The VasoGuard from VIASYS Neurocare ... forward in physiologic vascular diagnosis. Exceptional ... and system reliability. , ,VasoGuard delivers ... The unique QuickConnect arm for cuff ...
Medicine Products: